Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference21 articles.
1. HOVON. https://hovon.nl/en/trials/ho155. Accessed 05 July 2022.
2. EMA. Assessment report of Midostaurin (Rydapt). https://www.ema.europa.eu/en/documents/assessment-report/rydapt-epar-public-assessment-report_en.pdf: European medicine agency—Committee for Medicinal Products for Human Use 2017. Accessed 05 July 2022.
3. Szolar DH, Korobkin M, Reittner P, Berghold A, Bauernhofer T, Trummer H, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology. 2005;234(2):479–85.
4. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.
5. Tzogani K, Yu Y, Meulendijks D, Herberts C, Hennik P, Verheijen R, et al. European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis. ESMO Open. 2019;4(6): e000606.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Midostaurin;Reactions Weekly;2022-12-03